12 Jun R&D Underspending in India: Systemic & Cultural Roots
This article covers “Daily Current Affairs”
SYLLABUS MAPPING : GS Paper 2 , 3 : Governance , Economy , Science and Technology
FOR PRELIMS : GERD, ANRF, GII, DSIR, DST, DPIIT, CSIR, DRDO, ISRO,
FOR MAINS : The Anusandhan National Research Foundation (ANRF) — with ₹50,000 crore and the Prime Minister as Governing Board Chairman — is India’s most ambitious R&D reform in decades. Yet only 15% of the previous year’s R&D budget was utilised. Examine the institutional bottlenecks that prevent India from effectively deploying its R&D budget, and suggest governance reforms to ANRF’s design that can improve fund utilisation, bridge the lab-to-market gap, and incentivise private sector R&D investment in India.
India’s vast, protected domestic market allows firms to generate profits without world-class innovation. Export competition — the primary driver of R&D investment globally — is largely absent for most Indian firms. Why develop a better product when the existing one sells readily at home? CEA cites this as the most structurally respectable explanation.
India’s corporate sector underwent financialisation — shift from productive investment to financial return — before it developed manufacturing depth. India’s S&P 500 equivalents spend on buybacks and dividends rather than R&D. Lazonick: maximise shareholder value = maximise short-term stock price = suppress R&D. Executive stock options amplify this perverse incentive.
Colonial suppression of India’s textile industry and manufacturing communities re-oriented Indian enterprise toward commerce, intermediation, and arbitrage rather than production and innovation. The few families that retained/rebuilt manufacturing identity are evidence of what might have been — India’s manufacturing culture was systematically destroyed and never fully rebuilt.
Only 15% of the R&D budget was utilised in FY25–26 — proving the problem is not insufficient funding but institutional bottlenecks. Delays in appointing fund managers, rigid procurement processes, administrative compliance burden, and risk-aversion in public labs (CSIR, DRDO, DST departments) create structural underutilisation.
India produces massive research output (3rd largest in publications) but the “lab-to-market” translation gap is enormous. Academic research rarely becomes commercial technology; patent filing rates from universities are negligible; technology licensing revenues near zero. University-industry collaboration is structurally absent unlike in USA (Bayh-Dole Act model) or China (National Universities of Technology).
CEA notes cultural biases: risk aversion — Indians historically prefer safe government jobs; hierarchical epistemology — cultural deference to established knowledge over questioning; quick returns preferred — R&D’s 10–15 year payoff horizon conflicts with short-term profit culture. Democracy and uncertainty also make long-term R&D commitments structurally harder in polities seeking short-term political returns.
| Institution / Scheme | Nature & Function | Key Issue / Current Status |
|---|---|---|
| ANRF (Anusandhan National Research Foundation) | Established by ANRF Act, 2023; India’s apex body for R&D funding. 5-year, ₹50,000 crore ($10B) programme. Chaired by PM; governs research strategy across STEM and humanities. Modelled on NSF (USA) and NRF (South Korea). | Only 15% utilisation of allocated funds in FY25–26; bottlenecks in fund manager appointments (only BIRAC and TDB empanelled); institutional architecture still being built |
| CSIR (Council of Scientific & Industrial Research) | Network of 37 national laboratories under DSIR; key focus on applied research — drugs, aerospace, mining, food. Has delivered strategic gains (Covaxin platforms, materials) | Commercialisation of research remains weak; lab-to-market translation poor; funding heavily public; private sector collaboration limited |
| DRDO (Defence R&D Organisation) | Primary defence technology developer — Agni missiles, Arjun tank, Tejas LCA, BrahMos (joint). Budget ~₹23,000 crore (2026). Provides strategic autonomy in defence. | Civilian spillover from defence R&D is limited; DRDO budget absorption has improved but time-to-deployment remains long; private sector now allowed into defence R&D (2020 reforms) |
| DST (Department of Science and Technology) | Apex body for S&T policy; funds individual research grants, fellowships (INSPIRE, SERB), and technology incubators; coordinates international R&D cooperation | Only 61% budget utilisation (2022–23); grant disbursement delays; project completion rates low; gap between sanctioned and released funds |
| DSIR / DPIIT — R&D tax incentives | DSIR certifies industry R&D labs for 150% tax deduction on R&D expenditure; DPIIT manages DESH/PLI schemes that incentivise manufacturing R&D | Tax incentive uptake low — Indian companies still prefer dividends/buybacks; PLI schemes are production-linked, not specifically R&D-linked |
| National IPR Policy (2016) + Startup India | Aims to boost patent filing and commercialisation; Startup India provides R&D-oriented startups with tax exemptions (3 of 7 years), faster certification, and incubation support | India’s patent filings improving (90,000+ in FY24) but still ~1/10th of China’s; most patents by foreign entities; domestic innovation patents remain low |
- China’s GERD: $700 billion annually — nearly 10× India’s $71 billion — enabling dominance in AI, semiconductors, EVs, and biotech within 20 years
- State-directed R&D investment through 5-year plans with mandatory R&D targets for state-owned enterprises; 5% of revenue to R&D mandated for key industries
- Made in China 2025 — forced technology transfer, massive subsidies for domestic firms in 10 strategic sectors; now leading globally in EVs (BYD), solar panels, 5G (Huawei)
- National Universities of Technology — direct industry-academia pipelines; university IP commercialisation deeply embedded in Chinese university incentive structures
- Risk for India: China’s model involves non-market practices (WTO-incompatible subsidies, IP theft allegations) that India cannot/should not replicate; but the scale of ambition is instructive
- USA — Bayh-Dole Act (1980): Allowed universities to own IP from federally-funded research → catalysed Silicon Valley; universities licensed technology to spin-offs → Google, Genentech, many others emerged. India has no equivalent
- Israel — 5.6% GERD/GDP; mandatory R&D investment by defence contractors (similar to USA’s DARPA model); Unit 8200 (military intelligence unit) alumni found most successful tech startups; military-to-commercial technology transfer pipeline
- South Korea — Chaebol model: Samsung, LG, Hyundai mandated by government to invest heavily in R&D as condition for market protection; Korean firms now global technology leaders
- Common thread: export competition drove R&D investment in all three countries; CEA’s point — India needs to create the same export-competitive pressure
- When corporations shift priorities from productive investment (R&D, capex, hiring) to financial returns (buybacks, dividends, M&A) — this is financialisation
- USA’s Lazonick (HBR): S&P 500 companies spent 54% of earnings on buybacks + 37% on dividends (2003–12) → only 9% for everything else including R&D
- “Maximise Shareholder Value” doctrine — optimising short-term stock price → suppresses long-horizon R&D (5–10 year payoff) in favour of quarterly earnings
- Executive stock options tie CEO pay to share price → CEOs rationally prefer buybacks (boost share price immediately) over R&D (uncertain, long-term)
- India replicated this problem before reaching the manufacturing depth that Germany, Japan, or Korea had when they financialised — making India’s situation structurally more dangerous
- Global norm: Private sector (industry) contributes 70–75% of a country’s GERD; government contributes 25–30%
- India’s split: Government: 60%, Private: 40% — completely inverted. Indian corporates are under-investing in R&D relative to their global peers
- In USA, Germany, Japan, Korea: top firms (Apple, ASML, Toyota, Samsung) each individually spend more on R&D than many small countries’ entire GERD
- India’s top spenders: TCS, Infosys, Sun Pharma — primarily service/pharma R&D; manufacturing sector R&D extremely weak
- The PLI schemes are production-linked, not specifically R&D-linked; may build manufacturing capacity without building innovation capability
- ANRF (2023) is structurally the right response — modelled on NSF/NRF, apex R&D governance, ₹50,000 crore over 5 years; if institutional bottlenecks are resolved, it can transform India’s research landscape
- India is 3rd largest in research publications globally (2024) — the talent and intellectual capacity exists; the challenge is converting publications into patents and commercial technology
- Semiconductor Mission, Green Hydrogen Mission, Space Privatisation — create sectoral R&D anchors; if these missions succeed, they can kickstart innovation culture in specific high-tech domains
- India’s startup ecosystem (3rd largest globally) has shown innovation capability — Zomato, CRED, Zerodha, Meesho are technology innovators even if not deep-tech R&D companies
- Money without reform doesn’t work — ₹20,000 crore budgeted, ₹3,000 crore used; the problem is institutional plumbing not fiscal allocation; giving more money to broken institutions produces more waste
- Import dependence entrenched — India’s large firms find it cheaper to license technology from global leaders than to invest in domestic R&D; import substitution without R&D investment is a temporary fix
- Brain drain unaddressed — India’s best researchers continue to migrate to USA, UK, Germany for better research infrastructure, higher salaries, and intellectual freedom; ANRF cannot compete with MIT or Stanford unless institutional culture changes fundamentally
- Democracy-R&D tension — CEA’s provocative point: in a democracy with a large, diverse, uncertain electorate, long-horizon R&D investment is structurally harder to sustain across electoral cycles than in authoritarian systems (China)
- Fix ANRF’s institutional plumbing first: The ANRF’s 15% utilisation rate signals institutional bottlenecks must be cleared before throwing more money. Immediately empower more fund managers beyond BIRAC and TDB; adopt DARPA-inspired programme manager autonomy; use milestone-based disbursement rather than compliance-driven releases.
- Bayh-Dole equivalent for India: Enact a Technology Innovation and Patent Act that allows Indian public-funded universities and research institutes to own, patent, and commercialise their IP — creating the university spin-off ecosystem that produced Silicon Valley. Currently, IP from publicly funded research often reverts to the government with no commercialisation pathway.
- Export competitive pressure on firms: India must use FTAs, trade missions, and PLI’s export obligations to drive Indian firms into export markets — where they will face quality and technology competition that forces R&D investment. The CEA’s captive market thesis implies the solution is reducing domestic market protection for incumbent firms.
- Reform executive compensation: SEBI should restrict excessive stock buybacks by companies that spend below a minimum R&D-to-revenue threshold (say, 3% for manufacturing companies). Link CEO long-term incentive plans to R&D output metrics (patents, products commercialised) rather than purely to share price performance.
- Military-to-commercial R&D pipeline: India must deliberately create a DRDO/defence-to-civilian technology spillover mechanism — on the Israeli/US model. Declassifying and commercialising defence R&D outputs (materials, radar, communications, cybersecurity) through DPIIT-facilitated licensing can jumpstart civilian innovation at low marginal cost.
- Reverse brain drain with competitive research environment: ANRF fellowships and research chairs must offer globally competitive compensation, guaranteed 5-year research autonomy, and international collaboration rights. India’s diaspora (IITs-in-USA) must be actively recruited back with “Vaapsi” (return) incentive packages — following Denmark’s and South Korea’s successful brain-gain models.
“India’s R&D underspending is not primarily a fiscal problem — it is a structural and cultural pathology rooted in colonial de-industrialisation, the financialisation of corporate India, and a captive domestic market that insulates firms from competitive pressure.” Critically examine Chief Economic Adviser V. Anantha Nageswaran’s diagnosis of India’s R&D crisis. What institutional, policy, and cultural reforms are needed to move India’s GERD from 0.64% to 2% of GDP by 2047 as required for Viksit Bharat?
- Why Are Government Schools Shutting Down? - August 3, 2026
- Analysing the Supreme Court’s Judgment on Sex Work - August 3, 2026
- Strong Health Systems for All with Better Public Spending - August 3, 2026

No Comments